Literature DB >> 22454055

Exon skipping mutations in neurofibromatosis.

Emanuele Buratti1, Diana Baralle.   

Abstract

Defects at the level of pre-mRNA splicing represent a common source of disease mutations in almost all known diseases with a genetic aetiology. In general, it is commonly accepted that 15% of all pathogenic mutations are caused by splicing defects. However, this is probably a conservative estimate since clinical practice has only recently begun to routinely assess for this types of abnormalities. Therefore, it is expected that many currently unclassified or apparently harmless genetic variants will really turn out to be splicing-affecting defects. It is also well known that some genes are more susceptible than others to alterations in their splicing processes. Among these genes, one of the most representative is the NF-1 gene. In this gene, almost 50% of all reported disease-causing mutations can be directly attributed to alterations of the pre-mRNA process. In this chapter, we review the splicing process of the NF-1 gene and the most commonly used methods to identify splicing alterations. In particular, we provide practical notes on how to perform this analysis to maximize the chance of correctly identifying aberrant pre-mRNA splicing events in this gene.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22454055     DOI: 10.1007/978-1-61779-767-5_5

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  2 in total

Review 1.  Oral Manifestations and Molecular Basis of Oral Genodermatoses: A Review.

Authors:  Kiran Kumar; A S Shilpasree; Meenakshi Chaudhary
Journal:  J Clin Diagn Res       Date:  2016-05-01

Review 2.  Mutation-Directed Therapeutics for Neurofibromatosis Type I.

Authors:  Andre Leier; David M Bedwell; Ann T Chen; George Dickson; Kim M Keeling; Robert A Kesterson; Bruce R Korf; Tatiana T Marquez Lago; Ulrich F Müller; Linda Popplewell; Jiangbing Zhou; Deeann Wallis
Journal:  Mol Ther Nucleic Acids       Date:  2020-04-29       Impact factor: 8.886

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.